tbuckley/cabot-search huggingface dataset:
AB1008 CHARACTERIZATION OF THE RISK OF OSTEOPOROSIS IN A COHORT OF RHEUMATIC PATIENTS DURING 10 YEARS OF FOLLOW-UP.
Authors: L. Dulcey, J. Theran, D. Villamizar, E. Espinoza, R. Caltagirone, H. Gonzalez, J. Lopez, A. Quintero, R. Parales, M. Aguas
Journal: Annals of the Rheumatic Diseases (2022)

Background Osteoporosis is the most common cause of fractures. The lifetime risk of fracture after age 50 is 40% for women and 13% for men. Objectives Patients with rheumatological diseases are at greater risk for the development of osteoporosis, either due to the natural history of their disease or due to the side effects of the medications used. We proposed to carry out this study. Methods Retrospective study aimed at determining the presence of risk factors in patients over 50 years of age who attend the Rheumatology service of a hospital in Venezuela during a follow-up from January 2010 to December 2020 in order to know these risk factors and thus generate strategies that allow better orienting the care of these patients. Results The main group of patients was constituted by the female gender and the ages between 50 and 65 years. The main rheumatological pathology was rheumatoid arthritis, followed by Lupus, Osteoarthritis in 3 place and finally in the last box other entities other than those indicated. Graph 1. Prevalence of Osteoporosis due to rheumatological pathologies. Conclusion The 2 main risk factors for the development of osteoporosis were the use of steroids and obesity. The main type of osteoporosis of the 2 categories described was non-severe. The main group of rheumatological patients most associated with osteoporosis were those with rheumatoid arthritis. 12% of the patients with rheumatic disease and osteoporosis did not have appropriate therapy. References [1]Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2014 Jul;142:155-70. doi: 10.1016/j.jsbmb.2013.09.008. [2]Gambacciani M, Levancini M. Management of postmenopausal osteoporosis and the prevention of fractures. Panminerva Med. 2014 Jun;56(2):115-31. [3]McLendon AN, Woodis CB. A review of osteoporosis management in younger premenopausal women. Womens Health (Lond). 2014 Jan;10(1):59-77. doi: 10.2217/whe.13.73. [4]Eriksen EF, Díez-Pérez A, Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone. 2014 Jan;58:126-35. doi: 10.1016/j.bone.2013.09.023. Disclosure of Interests None declared
Retraction Note: Alpha-synuclein overexpression in the olfactory bulb initiates prodromal symptoms and pathology of Parkinson’s disease
Authors: Haichen Niu, Lingyu Shen, Tongzhou Li, Chao Ren, Sheng Ding, Lei Wang, Zhonghai Zhang, Xiaoyu Liu, Qiang Zhang, Deqin Geng, Xiujuan Wu, Haiying Li
Journal: Translational Neurodegeneration (2022)
Istanbul Protocol 2022 empowers health professionals to end torture
Authors: Vincent Iacopino, Rohini J Haar, Michele Heisler, James Lin, Şebnem Korur Fincancı, Chris Esdaile, Jens Modvig, Nora Sveaass, Vivienne H Nathanson, Nils Melzer, Juliet Cohen
Journal: The Lancet (2022)
Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts
Authors: Peter Martin, Jonathon B. Cohen, Michael Wang, Anita Kumar, Brian Hill, Diego Villa, Jeffrey M. Switchenko, Brad Kahl, Kami Maddocks, Natalie S. Grover, Keqin Qi, Lori Parisi, Katherine Daly, Angeline Zhu, Gilles Salles
Journal: Journal of Clinical Oncology (2022)

Commonly used first-line (1L) treatments for mantle cell lymphoma include high-dose cytarabine-based induction followed by autologous stem-cell transplant (ASCT) for younger patients and several chemoimmunotherapy regimens for older patients. Continuous debates exist on the role of ASCT in younger patients and maintenance rituximab (MR) after bendamustine plus rituximab (BR).Retrospective data from 4,216 patients with mantle cell lymphoma in the Flatiron Health electronic record-derived deidentified database diagnosed between 2011 and 2021, mostly in US community oncology settings, were evaluated for treatment patterns and outcomes. The efficacy findings with ASCT and MR were validated in an independent cohort of 1,168 patients from 12 academic centers.Among 3,614 patients with documented 1L treatment, BR was the most used. Among 1,265 patients age < 65 years, 30.5% received cytarabine-based induction and 23.5% received ASCT. There was no significant association between ASCT and real-world time to next treatment (hazard ratio [HR], 0.84; 95% CI, 0.68 to 1.03; P = .10) or overall survival (HR, 0.86; 95% CI, 0.63 to 1.18; P = .4) among ASCT-eligible patients. Among MR-eligible patients, MR after BR versus BR alone was associated with a longer real-world time to next treatment (HR, 1.96; 95% CI, 1.61 to 2.38; P < .001) and overall survival (HR, 1.51; 95% CI, 1.19 to 1.92; P < .001). The efficacy findings were consistent in the validation cohort.In this large cohort of patients treated primarily in the US community setting, only one in four young patients received cytarabine or ASCT consolidation, suggesting the need to develop treatments that can be delivered effectively in routine clinical practice. Together with the validation cohort, data support future clinical trials exploring regimens without ASCT consolidation in young patients, whereas MR should be considered for patients after 1L BR and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
POS1110 WHAT FACTORS ARE ASSOCIATED WITH THE DEVELOPMENT OF PAIN AFTER TOTAL JOINT REPLACEMENT?
Authors: V. Nesterenko, A. Karateev, M. Makarov, E. Bialik, S. Makarov, V. Bialik, M. Nurmukhametov, A. Roskidailo, N. Burikov
Journal: Annals of the Rheumatic Diseases (2022)

Background Chronic postoperative pain (CPP) is one of the most common complications of total hip (HJ) and knee (CJ) arthroplasty (TA). The search for the factors that determine this pathology is an urgent scientific and practical task. Objectives To determine the factors associated with the development of CPP in patients who underwent TA, CJ or HJ. Methods The study group consisted of 124 patients with osteoarthritis of the knee or hip joint, mean age 63.6 + 9.9 years, 63% of women and 37% of men, who in 2019-2020 year done out by TA KJ or HJ. The development of CPP was assessed after 3 and 6 months. telephone survey of patients. This complication was diagnosed in the presence of moderate to severe pain (≥40 mm on a visual analogue scale, VAS), persisting for at least 3 months, causing concern in patients and / or requiring regular use of analgesics. A comparison was made between the groups of patients with CPP and the absence of CPP for a number of factors determined in the preoperative period. Results The incidence of CPP was 27.4%. There were no differences in the incidence of CPP in patients who underwent TA CJ and TA HJ: 28.1% and 26.9%, respectively (p = 0.88). The presence of CPP was significantly associated with such preoperative indicators as a higher body mass index (BMI), a higher intensity of pain at rest, higher values of the WOMAC pain index, WOMAC and WOMAC stiffness in general, and the severity of symptoms of neuropathic pain. (PainDetect questionnaire), signs of depression and anxiety (HADS questionnaire). The risk of developing CPP was significantly higher (p &lt;0.05) in patients with BMI&gt; 30 kg / m2 - odds ratio (OR) 2.755 (95% confidence interval, CI 1.053-7.206), for pain at rest ≥40 mm VAS - OR 1.349 (95% CI 0.478-3.803), Pain Detect score ≥13 - OR 3.598 (95% CI 1.048-12.36), depression score HADS ≥8 - OR 2.193 (95% CI 0.745-6.454), number of pain sources ≥ 2 - OR 6.996 (95% CI 2.358-20.756). Conclusion The risk of CPP after TA CJ and HJ is higher in patients with overweight, high preoperative pain, signs of neuropathic pain and depression, and in the presence of several sources of musculoskeletal pain (except for the affected joint planned for TA). Disclosure of Interests None declared
POS1578-PARE TO OBTAIN GREATER AWARENESS OF ARTHRITIS AND THE DANISH ARTHRITIS ASSOCIATION BY MEDIA COVERAGE
Authors: J. Lüthcke
Journal: Annals of the Rheumatic Diseases (2022)

Background Despite arthritis being among the most common diseases in Denmark, the overall personal consequences followed are generally unknown. You don’t die of arthritis. This is reflected in the population’s general knowledge of The Danish Arthritis Association of a mere 57 %, despite being Denmark’s third largest patient organisation. Objectives To obtain greater awareness of arthritis and the Danish Arthritis Association by media coverage Methods We use case stories strategically in our offensive political agenda. By presenting a good case story with a personal, yet wide perspective, we quite often succeed in getting our agenda in the media – as personal and emotional case stories are more likely stories to be chosen by journalists than political solutions from organisations like ours. On social media (especially Facebook and Instagram) we also use case stories to a great extent – 2 – 3 times a week. Our followers like to read stories about people who struggle with the same issues as themselves – and to reflect their own issues. Whether they are newly diagnosed or have lived with arthritis for a long time. In general, we get good response on these personal case stories. Many likes, and often our followers share their own experience with each other and pass on good advice. Helping out the media The media and journalists are always in need of case stories to back up their articles and agendas. We have introduced the principle of always being willing to help the media with case stories. By providing cases with arthritis– even though the issues aren’t exclusively about arthritis, we help solving a problem, as well as we manage to turn the agenda into a story about arthritis as well. Examples are corona, vaccination, deferred surgeries, lack of coherence in the health system. What does it take to use cases? As an organisation, you have a responsibility to take care of your cases by informing them of what it means to be in the media. They must be prepared and helped out – also along the way. It is also important to choose cases who are well spoken and not afraid to express themselves. Debate group Some of the topics such as coherence in health care, are immediately academic topics, and difficult to understand – and therefore more difficult to get covered in the media. We have successfully initiated a debate group consisting of a small group of young arthritis patients, whom we have taught how to write debate posts. By telling their own personal stories – often with an underlying political angle – these articles have been published in the major national newspapers. Results We have succeeded in getting media coverage in both women’s magazines, tabloid newspapers, national newspapers as well as radio and television. Conclusion It is a fairly simple concept that easily can be copied by other patient organisations despite size. Disclosure of Interests None declared
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
Authors: Shaji Kumar, Lawrence Baizer, Natalie S. Callander, Sergio A. Giralt, Jens Hillengass, Boris Freidlin, Antje Hoering, Paul G. Richardson, Elena I. Schwartz, Anthony Reiman, Suzanne Lentzsch, Philip L. McCarthy, Sundar Jagannath, Andrew J. Yee, Richard F. Little, Noopur S. Raje
Journal: Blood Cancer Journal (2022)

Abstract A wide variety of new therapeutic options for Multiple Myeloma (MM) have recently become available, extending progression-free and overall survival for patients in meaningful ways. However, these treatments are not curative, and patients eventually relapse, necessitating decisions on the appropriate choice of treatment(s) for the next phase of the disease. Additionally, an important subset of MM patients will prove to be refractory to the majority of the available treatments, requiring selection of effective therapies from the remaining options. Immunomodulatory agents (IMiDs), proteasome inhibitors, monoclonal antibodies, and alkylating agents are the major classes of MM therapies, with several options in each class. Patients who are refractory to one agent in a class may be responsive to a related compound or to a drug from a different class. However, rules for selection of alternative treatments in these situations are somewhat empirical and later phase clinical trials to inform those choices are ongoing. To address these issues the NCI Multiple Myeloma Steering Committee formed a relapsed/refractory working group to review optimal treatment choices, timing, and sequencing and provide recommendations. Additional issues considered include the role of salvage autologous stem cell transplantation, risk stratification, targeted approaches for genetic subsets of MM, appropriate clinical trial endpoints, and promising investigational agents. This report summarizes the deliberations of the working group and suggests potential avenues of research to improve the precision, timing, and durability of treatments for Myeloma.
AB1038 PEGLOTICASE URATE-LOWERING RESPONSE FOLLOWING COVID-RELATED GAP IN THERAPY: EXPERIENCES OF ONE RHEUMATOLOGIST
Authors: D. Mandel, P. Scott, B. Lamoreaux
Journal: Annals of the Rheumatic Diseases (2022)

Background When uncontrolled gout cannot be managed with oral urate-lowering therapies, pegloticase is one of the few remaining treatment options. Patients receiving infusion therapies experienced treatment interruptions due to the COVID-19 pandemic. As with other biologic therapies, patients can develop anti-drug antibodies (ADAs) against pegloticase, and longer infusion intervals can result in higher rates of pegloticase immunogenicity. 1 The literature suggests that co-administering an immunomodulator with pegloticase can markedly decrease the proportion of patients who develop ADAs, 2 increasing the proportion with sustained urate-lowering response. 3 Objectives This case series reports one rheumatologists’ experience with a gap in pegloticase therapy during the COVID-19 pandemic. Methods Uncontrolled gout patients who underwent pegloticase treatment during 2019/2020 and had a gap in therapy of ≥28 days were identified. Patient, clinical, and treatment (number post-gap infusions, immunomodulation co-therapy) characteristics were retrospectively examined, along with urate-lowering response following therapy interruption. Patients who had a serum urate (SU) &lt;6 mg/dL after the last post-gap pegloticase infusion were considered to have recaptured response. Results 7 patients (5 men, 64.3±13.5 years, pretherapy sUA: 7.76±2.47 mg/dL, 6 had tophi) were included with 2 remaining on therapy at data collection. Eleven gaps were noted with an average gap duration of 11.4±9.3 weeks (median: 9 weeks). For the last gap in therapy, patients received 13.9±7.0 infusions (range: 4-22) before the gap and 7.0±4.1 infusions (range: 2-14) after (Figure 1). Four patients (57%; Patients 1, 2, 5, 7) had recaptured urate-lowering at last pegloticase infusion, all of whom began immunomodulation (3 methotrexate, 1 mycophenolate mofetil/hydroxychloroquine) prior to resuming pegloticase. Of the 3 patients without response recapture, 2 initiated MTX after resuming pegloticase. 4 patients (57%) experienced ≥1 AE, including mild infusion reaction (n=1), acute gout flare (n=2), clinically meaningful decrease in eGFR (14.8 ml/min/1.73m 2 , n=1), heart attack (n=1), and anemia (n=1). Conclusion These cases suggest that it may be possible to recapture urate-lowering response to pegloticase in some patients, particularly in the presence of immunomodulation. These preliminary findings are important to this vulnerable patient population, particularly during the COVID-19 pandemic. Further study is needed to confirm our findings. References [1]Sundy JS, et al. JAMA 201;306:711-20. [2]Song Y, et al. Arthritis Rheum 2020;72 [3]Keenan RT, et al. Semin Arthritis Rheum 2021, 51:347-52. Acknowledgements Medical writing support provided by Lissa Padnick-Silver PhD, an employee of and stockholder in Horizon. Disclosure of Interests David Mandel: None declared, Patricia Scott: None declared, Brian LaMoreaux Shareholder of: Horizon Therapeutics, Employee of: Horizon Therapeutics
AB1169 IMMUNOMODULATORY EFFECTS OF SARS-CoV-2 VACCINATION: INCREASE OF REGULATORY T CELLS AFTER mRNA VACCINE
Authors: F. La Gualana, F. Villani, G. Cusano, L. Gragnani, L. Stefanini, S. Santini, S. Basili, M. Casato, M. Fiorilli, M. Visentini
Journal: Annals of the Rheumatic Diseases (2022)

Background Besides the ability to induce antigen-specific responses, vaccines can be endowed with immunomodulatory properties including the capacity to induce or downregulate regulatory T cells (Treg) that suppress adaptative and autoreactive immune responses (1). Objectives We asked if an anti-SARS-CoV-2 mRNA vaccine could also induce an accumulation of Treg cells in patients with mixed cryoglobulinemia vasculitis (MCV), who have a deficiency of Treg cells (2) and in healthy individuals. We also investigated immunologic variables possibly associated with a low immunogenicity of SARS-CoV-2 mRNA vaccine in patients with MCV (3). Methods We analyzed peripheral blood lymphocyte subpopulations and anti-SARS-CoV-2 serological response in 24 patients with MCV and 9 Healthy donors (HD) before and after 2 weeks after the second dose of the Pfizer/BioNTech vaccine. Results Among MCV patients we found 15 serological responders and 9 non-responders. All 5 seronegative patients treated recently with rituximab had &lt;5 B cells/µL, whereas the absolute B cell count was increased in 2 of 4 untreated patients due to monoclonal B cell lymphocytosis, with monoclonal cells representing more than 90% of B cells, associated with non-Hodgkin lymphoma. The percentage of pathologic CD21 low B cells was significantly increased in seronegative patients. Before receiving the Pfizer/BioNTech vaccine, patients with MCV had a significantly reduced frequency of Treg cells among CD4 + T cells compared to HD. After the second dose of the vaccine, there was in MCV patients a significant increase in the percent and absolute count of Treg among CD4+ T cells Concerning the pre-vaccination distribution of T cells subpopulations, including the percentages and absolute counts of total CD3 + , CD4 + , CD8 + , HLA-DR + activated, Treg or CD56 + natural killer T cells, we could not reveal any pattern significantly associated with lack of serological response to vaccine. Conclusion Our findings show that lack of immunoreactivity in patients with MCV may be associated with expansion of pathologic B cells and that anti-SARS-CoV2 mRNA vaccine may induce an increase of Treg cells. References [1]Krienke C. et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science. 2021 Jan 8;371(6525):145-153. [2]Boyer O. et al. CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood. 2004 May 1;103(9):3428-30. [3]Visentini M. et al. Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2. Ann Rheum Dis. 2021 Nov 24:annrheumdis-2021-221248. Disclosure of Interests None declared
What Is Carpal Tunnel Syndrome?
Authors: Kristin Walter
Journal: JAMA (2022)

What Is Carpal Tunnel Syndrome?The carpal tunnel is a narrow channel about 1 inch long between the wrist and the hand.This anatomic tunnel is formed by the bones on the back of the wrist and is covered by a thick band of connective tissue on the front (palm side) of the wrist, and contains tendons and the median nerve.Carpal tunnel syndrome occurs when the median nerve, which runs from the forearm to the palm of the hand, is compressed by swelling of other tissues within the carpal tunnel or by narrowing of the carpal tunnel.The median nerve provides sensation to the thumb, the index finger, the middle finger, and half of the ring finger and is responsible for movement of all of the fingers and the wrist.
AB0197 RHEUMATOID ARTHRITIS DISEASE ACTIVITY AND CERVICAL SPINE INVOLVEMENT
Authors: N. Bahaz, F. Mechid, C. Makhloufi-Dahou
Journal: Annals of the Rheumatic Diseases (2022)

Background The prevalence of cervical spine involvement in rheumatoid arthritis (RA) varies between 17 and 86%. Cervical spine involvement is in third place after hand-wrist and foot involvement. The activity of RA is manifested by inflammation of all joints. Objectives To study the characteristics of patients with rheumatoid arthritis and research a relationship between cervical spine involvement and disease activity in rheumatoid arthritis. Methods We conducted a multicenter, prospective, descriptive, cross-sectional study in 300 patients with RA between 2013-2018. We collected demographic data, Body mass index (BMI), disease duration, Disease Activity Score of 28 joints (DAS28), (Health Assessment Questionnaire (HAQ), CRP, ESR, the rheumatoid factor (RF), ACPA. A radiological assessment of the cervical spine was requested for all patients, including a radiograph of the cervical spine from the front with the mouth open, a neutral profile, and dynamic flexion and hyperextension views. The activity of RA was assessed by DAS28. We study the relationship between cervical spine involvement (CSI) and disease activity in RA. Results 80, 3% were female), sex ratio H/F) was 0,24, the mean age was 51, 17±12,68 years, the BMI was 26,11±5,25, 67, 66 % had comorbidities, the most frequent were osteoporosis (30%), obesity (24%), hypertension (21,7%). RA mean duration was 13±9 years, mean DAS 28 was 4,68±1,5 mean HAQ was 1,01±0,69, mean CRP was 15,50 ±12 mg/L, mean ESR was 41,89 ±26,8mm, rheumatoid factor was positive in 70,6% and ACPA were positives in 77,3%. The standard radiographs of cervical spine found 53 (17, 66%) patients with CSI The various lesions of the cervical spine were atlantoaxial subluxations 13%, 3,66% of lateral atloїdo-axoїd subluxations, vertical subluxations in 0,66%, C1C2 arthropathies in 2,33% spondylolisthesis in 2%, and 0,33% of spondylodiscitis. The results of the univariate and multivariate analysis did not find a relationship between CSI and DAS28A (p=0, 66). Conclusion Cervical spine involvement in rheumatoid arthritis was common in our study. We did not find a relationship between cervical spine involvement and disease activity in rheumatoid arthritis. References [1]M.Blom et al. Long-term follow-up of the cervical spine with conventional radiographs in patients with rheumatoid arthritis (RA).Scand J Rheumatol 2013; 42:281-8. [2]M. Del Grande et al. Cervical spine involvement early in the course of RA. Semin Arthritis Rheum 2014; 43(6):738-44. Disclosure of Interests None declared